Next Article in Journal
Comparative Evaluation of Open-Source Bioinformatics Pipelines for Full-Length Viral Genome Assembly
Next Article in Special Issue
Comparative Analyses of Antiviral Potencies of Second-Generation Integrase Strand Transfer Inhibitors (INSTIs) and the Developmental Compound 4d Against a Panel of Integrase Quadruple Mutants
Previous Article in Journal
Rapid and Visual Screening of Virus Infection in Sugar Beets Through Polerovirus-Induced Gene Silencing
Previous Article in Special Issue
Achievement of Primary Prevention Cardiometabolic Targets in Women with HIV: An Urgent Call to Action to Pursue Cardiovascular Health
 
 
Brief Report
Peer-Review Record

Probability of Starting Two-Drug Regimen (2DR) vs. Three-Drug Regimen (3DR) in ART-Naïve and ART-Experienced Person with HIV (PWH) Across the First Wave of COVID-19 Pandemic

Viruses 2024, 16(12), 1822; https://doi.org/10.3390/v16121822
by Alessandra Vergori 1,*, Nicola Gianotti 2, Alessandro Tavelli 3,4, Camilla Tincati 5, Andrea Giacomelli 6,7, Elena Matteini 8, Giuseppe Lapadula 9, Lucia Taramasso 10, Loredana Sarmati 11, Antonella D’Arminio Monforte 3,4, Andrea Antinori 1, Alessandro Cozzi-Lepri 12 and on behalf of the ICONA Foundation Study on behalf of the ICONA Foundation Study
Reviewer 2:
Viruses 2024, 16(12), 1822; https://doi.org/10.3390/v16121822
Submission received: 27 September 2024 / Revised: 14 November 2024 / Accepted: 22 November 2024 / Published: 23 November 2024
(This article belongs to the Collection Efficacy and Safety of Antiviral Therapy)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

The study by Vergori et al, describe the trends in the use of 2D vs 3D drug regimens of antiretroviral therapy (ART) drugs among ART naïve and ART experienced persons with HIV during the COVID-19 pandemic. This brief report is interesting to note that despite COVID-19 the use of ART of 2D/3D continued among HIV individuals.

The major limitation of this work is that most of the work is descriptive.

This study lacks any conclusive evidence to show any impact of COVID-19 between 2D and 3D regimen individuals.

However, these studies critical to understand and provides a clue for future pandemic scenarios that continuation of 2D/3D ART drugs is essential. The addition of the data on any clinical parameters would be valuable.

Figures 1 and 2 are confusing. Although the legend describes 2D vs 3D the data only shows 2D. The Y-axis should be denoted as 2D vs 3D ART drug regimens.     

Author Response

The study by Vergori et al, describe the trends in the use of 2D vs 3D drug regimens of antiretroviral therapy (ART) drugs among ART naïve and ART experienced persons with HIV during the COVID-19 pandemic. This brief report is interesting to note that despite COVID-19 the use of ART of 2D/3D continued among HIV individuals. 

The major limitation of this work is that most of the work is descriptive. 

This study lacks any conclusive evidence to show any impact of COVID-19 between 2D and 3D regimen individuals.

However, these studies critical to understand and provides a clue for future pandemic scenarios that continuation of 2D/3D ART drugs is essential. The addition of the data on any clinical parameters would be valuable.

Figures 1 and 2 are confusing. Although the legend describes 2D vs 3D the data only shows 2D. The Y-axis should be denoted as 2D vs 3D ART drug regimens.

 

We appreciate the reviewer’s comment and agree with  his/her perspective. The goal of our work was primarily descriptive,  specifically to evaluate the frequency of use of available treatment strategies in the ART-naïve and suppressed switch settings during a time of significant uncertainty in healthcare due to the lockdown caused by the COVID-19 pandemic.

 

In line with your suggestion of adding clinical parameters to the picture, we have now included some information on comorbidity in the descriptive tables.

 

Regarding the comment on the figures, we agree with the reviewer, and we have now corrected the Y axis to read “Proportion of PWH starting 2DR/ total (%)” for Figure 1 and “Proportion of PWH switching to 2DR /total (%)” for Figure 2.

 

Reviewer 2 Report

Comments and Suggestions for Authors

Dear authors:

 

In general, this is a well-written manuscript. Other points in this manuscript needed to be clarified are listed below:

 

Minor revisions:

1.     Materials and methods: Did you exclude experienced and viremic foreign PWH? Because you could have assumed those individuals to be naïve PWH. 

2.     What is the proportion of PWH in Italy who are positive for HBsAg? I think this factor could a source of bias or limitations in prescribing 2DR or 3DR.

3.     The study does not account for all potential confounders, such as socioeconomic status, which may have influenced access to healthcare services during the pandemic and could partially explain the shift in ART prescribing patterns. Maybe you could list this factor as one of limitations.

Comments for author File: Comments.pdf

Author Response

In general, this is a well-written manuscript. Other points in this manuscript needed to be clarified are listed below:

 

Minor revisions:

  1. Materials and methods: Did you exclude experienced and viremic foreign PWH? Because you could have assumed those individuals to be naïve PWH. 

 

We believe that it is unlikely that migrants enrolled in Icona had been treated before entering Italy. Icona cohort enrols ART-naive patients as the only inclusion criterion other than HIV-1 infection and the investigators are indeed very careful during the screening, in case of any doubt the PWH should not be enrolled. Nevertheless, being a migrant may be associated with lower access to 2DR and is likely that the pandemic. could have had a larger impact on the migrant population. We have now further adjusted our logistic regression model for nation of birth and results were similar.

 

In the ART-experienced group, all individuals with detectable viral load >50 copies/mL have been originally excluded. In this revised version, we have further excluded 64 participants for whom their viral load was missing.

 

  1. What is the proportion of PWH in Italy who are positive for HBsAg? I think this factor could a source of bias or limitations in prescribing 2DR or 3DR.

 

We thank the reviewer for pointing this out. Indeed, a HBsAg+ test may preclude the use of some 2DR regimens. In the original submission we had included 2 PWH among the ART-naïve (0.1%) and 262 (2%) HBsAg+ participants in the ART-experienced setting. In this revised version we have now excluded these 264 individuals.  

 

 

  1. The study does not account for all potential confounders, such as socioeconomic status, which may have influenced access to healthcare services during the pandemic and could partially explain the shift in ART prescribing patterns. Maybe you could list this factor as one of limitations

 

 

We thank the reviewer for this remark which we agree with. Unfortunately, socioeconomics or accurate scores for social deprivations are not collected in the Icona database. However, we do collect nation of birth as well as level of education and employment status which are often used as proxy of socioeconomical status. We have now further controlled for these variables in the logistic regression model and results were almost identical. We have now also added a sentence in the Discussion section to highlight this potential limitation (lines 202-204).

Round 2

Reviewer 1 Report

Comments and Suggestions for Authors

The manuscript is well-written.

Back to TopTop